• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    (NTRA) - Analyzing Natera's Short Interest

    7/23/24 2:00:25 PM ET
    $NTRA
    Medical Specialities
    Health Care
    Get the next $NTRA alert in real time by email

    Natera's (NYSE:NTRA) short percent of float has risen 15.19% since its last report. The company recently reported that it has 6.38 million shares sold short, which is 5.46% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.14 days to cover their short positions on average.

    Why Short Interest Matters

    Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.

    Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.

    See Also: List of the most shorted stocks

    Natera Short Interest Graph (3 Months)

    short_fig

    As you can see from the chart above the percentage of shares that are sold short for Natera has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.

    Comparing Natera's Short Interest Against Its Peers

    Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.

    According to Benzinga Pro, Natera's peer group average for short interest as a percentage of float is 6.80%, which means the company has less short interest than most of its peers.

    Did you know that increasing short interest can actually be bullish for a stock? This post by Benzinga Money explains how you can profit from it.

    This article was generated by Benzinga's automated content engine and was reviewed by an editor.

    Get the next $NTRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NTRA

    DatePrice TargetRatingAnalyst
    4/14/2026Outperform
    William Blair
    1/7/2026$300.00Buy
    Citigroup
    12/2/2025$265.00Overweight
    Morgan Stanley
    10/27/2025$172.00Underperform → Neutral
    BNP Paribas Exane
    9/22/2025$175.00Equal Weight
    Wells Fargo
    3/13/2025$251.00Outperform
    RBC Capital Mkts
    1/23/2025$200.00Overweight
    Barclays
    6/3/2024$142.00Buy
    Jefferies
    More analyst ratings

    $NTRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Sheena Jonathan

    4 - Natera, Inc. (0001604821) (Issuer)

    4/21/26 9:05:05 PM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC Form 3 filed by new insider Rubin Eric H

    3 - Natera, Inc. (0001604821) (Issuer)

    4/9/26 8:25:07 PM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC Form 4 filed by Rabinowitz Matthew

    4 - Natera, Inc. (0001604821) (Issuer)

    4/8/26 9:05:05 PM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on Natera

    William Blair initiated coverage of Natera with a rating of Outperform

    4/14/26 8:34:48 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Citigroup initiated coverage on Natera with a new price target

    Citigroup initiated coverage of Natera with a rating of Buy and set a new price target of $300.00

    1/7/26 9:12:45 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Morgan Stanley resumed coverage on Natera with a new price target

    Morgan Stanley resumed coverage of Natera with a rating of Overweight and set a new price target of $265.00

    12/2/25 8:28:19 AM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma

    Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today highlighted Allogene Therapeutics' (NASDAQ:ALLO) interim futility analysis from its registrational ALPHA3 trial for cemacabtagene ansegedleucel (cema-cel), an investigational allogeneic anti-CD19 CAR T therapy, in first-line (1L) consolidation large B-cell lymphoma (LBCL). The ALPHA3 trial is enrolling patients with LBCL who test positive for molecular residual disease (MRD) following 1L therapy. These patients are then randomized either to cema-cel, an investigational allogeneic anti-CD19 CAR T therapy developed by Allogene, or observation. The interim analysis showed that 58.3% of MRD-positive pat

    4/13/26 8:00:00 AM ET
    $ALLO
    $NTRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities

    Judge Awards 30% Ongoing Royalty to Natera for its MRD-Related Patents

    Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today provided an update on a recent decision issued by the United States District Court in the District of Delaware regarding Natera's litigation with ArcherDx and Invitae. In a decision issued on April 6, 2026, the Court ordered an ongoing royalty to Natera of 30% on post-injunction revenues from infringing MRD-related product sales that fall within the exceptions to the injunction, which was issued by the Court on November 21, 2023. The jury had awarded an effective royalty of 20.5% on pre-injunction revenues, which remains unchanged. With respect to the non-MRD products, the jury's verdict of patent v

    4/9/26 6:00:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera's Oncology Platform

    Data from >75,000 patients underscore advances in AI-driven virtual genomics, Signatera™-guided treatment monitoring, and continued expansion of MRD and other capabilities Natera, Inc. (NASDAQ:NTRA) a global leader in cell-free DNA and precision medicine, today announced that 20 abstracts, including two oral presentations, featuring data generated using its technologies will be presented at the 2026 American Association for Cancer Research® (AACR) Annual Meeting 2026, taking place April 17–22 in San Diego, CA. These presentations, developed in collaboration with leading academic and clinical partners, span multiple tumor types and applications, including artificial intelligence, digital

    4/7/26 6:00:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    SEC Filings

    View All

    SEC Form DEFA14A filed by Natera Inc.

    DEFA14A - Natera, Inc. (0001604821) (Filer)

    4/23/26 4:57:03 PM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC Form DEF 14A filed by Natera Inc.

    DEF 14A - Natera, Inc. (0001604821) (Filer)

    4/23/26 4:44:24 PM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Natera, Inc. (0001604821) (Filer)

    4/1/26 4:15:42 PM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Financials

    Live finance-specific insights

    View All

    Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma

    Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today highlighted Allogene Therapeutics' (NASDAQ:ALLO) interim futility analysis from its registrational ALPHA3 trial for cemacabtagene ansegedleucel (cema-cel), an investigational allogeneic anti-CD19 CAR T therapy, in first-line (1L) consolidation large B-cell lymphoma (LBCL). The ALPHA3 trial is enrolling patients with LBCL who test positive for molecular residual disease (MRD) following 1L therapy. These patients are then randomized either to cema-cel, an investigational allogeneic anti-CD19 CAR T therapy developed by Allogene, or observation. The interim analysis showed that 58.3% of MRD-positive pat

    4/13/26 8:00:00 AM ET
    $ALLO
    $NTRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities

    Natera Reports Fourth Quarter and Full Year 2025 Financial Results

    Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the fourth quarter and full year ended December 31, 2025. Recent Financial Highlights Generated total revenues of $665.5 million in the fourth quarter of 2025, compared to $476.1 million in the fourth quarter of 2024, an increase of 39.8%. Product revenues grew 39.8% over the same period. Generated a gross margin1 of 66.9% in the fourth quarter of 2025, compared to a gross margin1 of 62.9% in the fourth quarter of 2024. Generated total revenues of $2,306.1 million in the full year 2025, compared to $1,696.9 million in the full year 2024, an increase of 35.9%.

    2/26/26 4:05:00 PM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera to Report its Fourth Quarter and Full Year Results on February 26, 2026

    Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its fourth quarter and year ended Dec. 31, 2025, after the market closes on Feb. 26, 2026. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information Event: Natera's Fourth Quarter & Full Year 2025 Financial Results Date: February 26, 2026 Time: 1:30 p.m. PT (4:30 p.m. ET) Live Dial-In:   1-888-770-7321 (Domestic) 1-929-201-7107 (International) Conference ID: 7684785 Webcast: https://events.q4inc.com/at

    2/17/26 9:00:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Leadership Updates

    Live Leadership Updates

    View All

    Octave Bioscience Expands Leadership Team with Appointment of Kirk Stockwood Senior Vice President, Commercial

    Octave Bioscience, Inc., a commercial stage precision medicine company pioneering biomarker driven solutions for multiple sclerosis, Parkinson's disease and other neurodegenerative diseases today announced the appointment of Kirk Stockwood as Senior Vice President, Commercial. Mr. Stockwood will spearhead Octave's commercial strategy as the company scales operations and expands the reach of its precision neurology platform. Mr. Stockwood brings over 20 years of leadership experience in specialty diagnostics and tools, with a proven track record of commercial scaling within public and private companies. Most recently as Vice President of Sales at Quanterix, he led a global team focused on

    1/8/26 4:01:00 PM ET
    $NTRA
    Medical Specialities
    Health Care

    Experienced Biotech Executive and Deal Maker Joins Zephyr AI as Chief Business Officer

    Zephyr AI, Inc. ("Zephyr AI"), a company building novel transparent AI to address unmet needs across the full spectrum of precision medicine – from prevention to treatment – to improve patients' lives, today announced the appointment of Eric Lindquist as its new Chief Business Officer. "At Zephyr AI, we have set out to use artificial intelligence and machine learning to bring precision medicine to those suffering from cancer, and our goal is for patients everywhere to be able to find the right treatment, delivered by the right provider, when they need it, enabling them to live healthier and fuller lives," said Grant Verstandig, Co-Founder and Executive Chairman of Zephyr AI. "Eric has bee

    6/5/23 11:06:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera Appoints Ruth E. Williams-Brinkley to its Board of Directors

    Seasoned healthcare executive with extensive leadership experience in health plans, hospital operations, and physician relations Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced that Ruth E. Williams-Brinkley has been appointed to the Company's board of directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230223005436/en/(Photo: Business Wire) Williams-Brinkley has three decades of healthcare industry experience. She currently serves as president of Kaiser Permanente Health Plan of the Mid-Atlantic States (KPMAS), where she oversees the company's care delivery and health plan operations

    2/23/23 8:05:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Natera Inc.

    SC 13G/A - Natera, Inc. (0001604821) (Subject)

    11/14/24 4:02:50 PM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Natera Inc. (Amendment)

    SC 13G/A - Natera, Inc. (0001604821) (Subject)

    6/7/24 12:07:25 PM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Natera Inc. (Amendment)

    SC 13G/A - Natera, Inc. (0001604821) (Subject)

    2/14/24 4:06:56 PM ET
    $NTRA
    Medical Specialities
    Health Care